- Anthropic has established a wet lab in the San Francisco Bay Area.
- The Claude developer is expanding its work in biotechnology and AI-assisted drug research.
- Anthropic says the Anthropic biology lab is not specifically for drug discovery and is not conducting clinical trials.
- The expansion comes as Anthropic gives verified life sciences researchers broader access to its advanced AI models.
San Francisco, California, 18 September, (Brussels Morning Newspaper) – Anthropic has established a wet laboratory in the San Francisco Bay Area as the artificial intelligence company expands Claude’s role in biological research and drug development. The facility allows Anthropic to connect AI-generated scientific work with physical laboratory experiments, while the company says it intends to work alongside pharmaceutical groups rather than compete directly with them.
Anthropic biology lab adds real-world testing
Reuters reported on Friday that the AI company had quietly established the laboratory as part of its growing life sciences operation. Eric Kauderer-Abrams, Anthropic’s head of life sciences, confirmed that the company is conducting physical laboratory work.
Anthropic said the facility is “not for drug discovery specifically”. The company is instead exploring how AI and laboratory automation can support biological research, including work involving rare diseases and conditions that have historically been difficult to target with medicines.
Kauderer-Abrams told Reuters that experimental validation remains necessary even as AI becomes more capable.
“We believe that to do biology, the final test is still and will be for a while in real lab work.”
Anthropic is not conducting clinical trials, according to Reuters.
Anthropic expands Claude for life sciences
The laboratory development coincides with a wider expansion of Anthropic’s biology programme.
On 17 September, Anthropic launched its Life Sciences Verification Program, providing approved professionals with access to advanced Mythos, Opus and Sonnet models under safeguards designed specifically for biological research. The company said it had already onboarded dozens of organisations during early access and expects hundreds to enrol during the programme’s first week.
The programme supports work including drug discovery, research biology, clinical development and manufacturing. Applicants undergo checks covering research credentials, security standards and ethical research oversight.
Claude accelerates biomolecular modelling
Anthropic also disclosed new results on 17 September showing how Claude is being applied to computational biology.
The company said Claude optimised more than 30 open-source biomolecular modelling systems in just under four weeks, making them roughly four times faster on average. Anthropic is releasing the optimised code and has announced a protein-design competition with Adaptyv Bio that includes wet-lab validation for more than 5,000 designs.
Biological safety remains part of expansion
Anthropic is simultaneously strengthening controls around advanced biological capabilities. Its September threat-intelligence report described biological misuse as “one of the most serious risks of frontier AI models” and said newer systems can assist with increasingly complex scientific research.
The new laboratory therefore marks a significant step in Anthropic’s life sciences strategy: moving from AI-assisted computational biology towards testing scientific work in physical laboratory conditions while maintaining controlled access to its most capable biology-focused models.
